Pembroke Management LTD Trims Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Pembroke Management LTD cut its stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 12.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 921,919 shares of the company's stock after selling 129,221 shares during the quarter. Stevanato Group makes up approximately 2.6% of Pembroke Management LTD's holdings, making the stock its 15th biggest position. Pembroke Management LTD owned about 0.30% of Stevanato Group worth $20,089,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in STVN. nVerses Capital LLC bought a new position in Stevanato Group in the 3rd quarter worth approximately $84,000. Hardy Reed LLC boosted its stake in Stevanato Group by 8.2% in the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock worth $222,000 after purchasing an additional 840 shares during the period. Lindenwold Advisors INC boosted its stake in Stevanato Group by 13.5% in the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company's stock worth $239,000 after purchasing an additional 1,415 shares during the period. Raymond James Trust N.A. boosted its stake in Stevanato Group by 22.6% in the 3rd quarter. Raymond James Trust N.A. now owns 12,556 shares of the company's stock worth $251,000 after purchasing an additional 2,317 shares during the period. Finally, Captrust Financial Advisors boosted its stake in Stevanato Group by 12.7% in the 3rd quarter. Captrust Financial Advisors now owns 13,100 shares of the company's stock worth $262,000 after purchasing an additional 1,480 shares during the period.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Bank of America upped their price target on Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Wolfe Research started coverage on Stevanato Group in a report on Friday, December 13th. They set an "outperform" rating and a $28.00 price objective on the stock. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of €28.60 ($29.79).

Stevanato Group Price Performance

Shares of STVN traded up €0.24 ($0.25) during mid-day trading on Friday, hitting €20.71 ($21.57). 168,700 shares of the stock were exchanged, compared to its average volume of 334,744. The company has a market cap of $6.27 billion, a PE ratio of 44.06, a price-to-earnings-growth ratio of 7.15 and a beta of 0.56. Stevanato Group S.p.A. has a 52-week low of €16.56 ($17.25) and a 52-week high of €34.00 ($35.42). The firm has a 50-day moving average of €21.76 and a two-hundred day moving average of €20.54. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.